Clinical Trials

Gastro-focused pharmaceutical company begins clinical trials for antacid capsules

Published in Medical Letter on the CDC and FDA, September 26th, 2004

Santarus, Inc. (SNTS), a pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, has initiated a pivotal pharmacokinetic/pharmacodynamic (PK/PD) clinical trial to evaluate Zegerid 40 mg capsules, an immediate-release formulation of the proton pump inhibitor (PPI) omeprazole.

The primary objective of this newly initiated clinical trial is to evaluate whether the 40 mg immediate-release Zegerid (omeprazole) capsules are pharmacokinetically equivalent to 40 mg delayed-release omeprazole capsules with respect to total systemic bioavailability.

The trial will also assess whether Zegerid capsules and the delayed-release...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-09-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry